Publications
Galen, J.E. and M.M. Levine. A “flawless” live vector vaccine strain: Can it be engineered? Trends in Microbiology. 2001. 9: 372-376.
Wang, J.Y., M. F. Pasetti, F. R. Noriega, R. J. Anderson, S. S. Wasserman, J.E. Galen, M. B. Sztein, and M.M. Levine. Construction, characterization and immunogenicity of attenuated delta guaBA Salmonella enterica serovar Typhi strain CVD 915. Infect. Immun. 2001. 69: 4734-4741.
Altboum, Z., E.M. Barry, G. Losonsky, J.E. Galen, and M.M. Levine. Attenuated Shigella flexneri 2a delta guaBA strain CVD1204 expressing enterotoxigenic Escherichia coli (ETEC) CS2 and CS3 fimbriae as a live mucosal vaccine against Shigella and ETEC infection. Infect. Immun. 2001; 69: 3150-3158.
Orr, N., J.E. Galen, and M.M. Levine. Novel use of anaerobically induced promoter, dmsA, for controlled expression of Fragment C of tetanus toxin in live attenuated Salmonella enterica serovar Typhi strain CVD 908-htrA. Vaccine. 2001; 19: 1694-1700.
Altboum, Z., M.M. Levine, J.E. Galen, and E.M. Barry. Genetic characterization and immunogenicity of coli surface antigen 4 from enterotoxigenic Escherichia coli when it is expressed in a Shigella live-vector strain. Infect. Immun. 2003; 71: 1352-1360.
Galen, J.E., L. Zhao, M. Chinchilla, J.Y. Wang, M.F. Pasetti, J. Green, and M.M. Levine. Adaptation of the endogenous Salmonella Typhi clyA hemolysin for antigen export enhances the immunogenicity of anthrax protective antigen domain 4 expressed by the attenuated live vector vaccine strain CVD 908-htrA. Infect. Immun. 2004. 72: 7096-7106.
Stokes MG, Titball RW, Neeson BN, Galen JE, Walker NJ, Stagg AJ, Jenner DC, Thwaite JE, Nataro JP, Baillie LW, Atkins HS. Oral administration of a Salmonella enterica-based vaccine expressing Bacillus anthracis protective antigen confers protection against aerosolized B. anthracis. Infect. Immun. 2007. 75:1827-34.
Chinchilla M, Pasetti MF, Medina-Moreno S, Wang JY, Gomez-Duarte OG, Stout R, Levine MM, Galen JE. Enhanced immunity to Plasmodium falciparum circumsporozoite protein (PfCSP) by using Salmonella enterica serovar Typhi expressing PfCSP and a PfCSP-encoding DNA vaccine in a heterologous prime-boost strategy. Infect. Immun. 2007. 75:3769-79.
Fang CM, J.Y. Wang, M. Chinchilla , M.M. Levine, W.C. Blackwelder, and J.E. Galen. Use of mchI encoding immunity to the antimicrobial peptide microcin H47 as a plasmid selection marker in attenuated bacterial live vectors. Infect. Immun. 2008. 76: 4422-4430.
Galen JE, M. Chinchilla, M.F. Pasetti, J.Y. Wang, L. Zhao, I. Arciniega-Martinez, D.J. Silverman, and M.M. Levine. Mucosal immunization with attenuated Salmonella Typhi expressing anthrax PA83 primes monkeys for accelerated serum antibody responses to parenteral PA83 vaccine. J. Infect. Dis. 2009. 199: 326-35.
Galen, J.E., M.F. Pasetti, S.M. Tennant, P. Olvera-Ruiz, M.B. Sztein, M.M.Levine. Salmonella enterica serovar Typhi Live Vector Vaccines Finally Come of Age. 2009. Immunol. Cell Biol. In press.
